Imagine a world without disease. Sounds utopian? AI just made it a multibillion-dollar bet to discover drugs – and forget Big ...

AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

Healthcare giants AbbVie and Abbott Laboratories are both Dividend Kings. They should maintain their dividend growth habits ...

AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing a long-acting amylin analogue from Denmark's Gubra in a deal valued at more than $2.2 billion. The ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut ...

Boehringer Ingelheim and partner Zealand Pharma have reported new clinical data in obesity for their dual glucagon/GLP1 agonist BI 456906, setting up a possible challenge to emerg ...

Gubra AS 70.55 -1.95% Mkt capEUR - IndustryBiotechnology 005257.KS Green Cross Holdings Corporation 48,300.00 -5.66% Mkt capKRW 731.75B IndustryBiotechnology GMAB.CO Genmab A/S 1,433.50 -0.52% Mkt ...